SRPT250117C143000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics
Sarepta Therapeutics Analyst Ratings
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler
Sarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy Rating
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $195
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165
RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $217
Sarepta Therapeutics (SRPT) Gets a Buy From Bank of America Securities
Jefferies Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $165
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)
Sarepta Therapeutics: Buy Rating Backed by Elevidys Growth and Diversified Pipeline
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys Projections
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target